Litigation Details for SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS INC. (D.N.J. 2013)

SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS INC. (D.N.J. 2013)

Docket		Date Filed	2013-08-07
Court	District Court, D. New Jersey	Date Terminated	2016-02-18
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Joel Schneider
Parties	ACTAVIS PHARMA, INC.
Patents	7,722,898; 7,910,131; 8,617,600
Attorneys	CHARLES A. WEISS
Firms	Holland & Knight LLP
Link to Docket	External link to docket

Details for SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS INC. (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-08-07				External link to document

Supernus Pharmaceuticals v. Actavis, 1:13-cv-04740: Litigation Summary and Patent Analysis

Last updated: August 13, 2026

Supernus Pharmaceuticals sued Actavis in the U.S. District Court for the District of New Jersey after Actavis filed an abbreviated new drug application seeking approval for a generic version of Trokendi XR, Supernus’s extended-release topiramate product. The case was a Hatch-Waxman Paragraph IV action focused on Supernus’s extended-release formulation patent estate. The litigation was resolved before a reported merits judgment, and the public record does not disclose the material commercial terms of the resolution.

What drug and patents were involved in Supernus v. Actavis?

The case concerned Trokendi XR, an extended-release formulation of topiramate approved by the FDA for the preventive treatment of migraine headaches and as adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.

Product and regulatory details

Item	Detail
Brand	Trokendi XR
Active ingredient	Topiramate
Dosage form	Extended-release oral capsule
Sponsor	Supernus Pharmaceuticals, Inc.
FDA application	NDA 202535
FDA approval	Aug. 16, 2013
Litigation defendant	Actavis Inc. and related Actavis entities
Court	U.S. District Court for the District of New Jersey
Case number	1:13-cv-04740
Action type	Hatch-Waxman patent litigation
Likely statutory basis	35 U.S.C. § 271(e)(2)

Supernus’s complaint followed Actavis’s Paragraph IV certification to patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The certification asserted that the relevant patents were invalid, unenforceable, or would not be infringed by Actavis’s proposed generic product.

The principal patent associated with the Trokendi XR formulation was U.S. Patent No. 8,298,589. The patent covered extended-release topiramate formulations and related pharmaceutical compositions. Supernus later obtained additional patents associated with the product, including U.S. Patent No. 8,747,897. The precise patents asserted in the initial complaint and any later amended pleadings should be distinguished from patents subsequently listed for Trokendi XR.

What was the legal basis of Supernus’s claims?

Supernus alleged that Actavis’s ANDA filing itself constituted an artificial act of infringement under Section 271(e)(2) of the Patent Act. The claim did not depend on commercial launch of the generic. The filing of an ANDA containing a Paragraph IV certification created the jurisdictional basis for the infringement action.

The dispute centered on whether Actavis’s proposed extended-release topiramate product fell within the scope of Supernus’s formulation claims. The relevant issues in this type of proceeding typically include:

• Whether the generic product contains the claimed extended-release matrix or release-control system.
• Whether the formulation satisfies limitations concerning dissolution or release profiles.
• Whether the asserted claims are anticipated or obvious.
• Whether the patent specification adequately supports the asserted claims.
• Whether the patent is enforceable, including potential inequitable-conduct defenses.
• Whether the generic applicant’s proposed labeling induces infringement of any method-of-use claims.

The public record identifies the case as a formulation patent dispute rather than a dispute over topiramate’s basic active-ingredient composition. That distinction is commercially important. Topiramate itself was an established active ingredient, so the principal barrier to generic entry depended on Supernus’s extended-release delivery technology and any surviving method-of-use or formulation claims.

When did Supernus file the case against Actavis?

Supernus filed the action in 2013 in the District of New Jersey after receiving Actavis’s Paragraph IV notice. The case number, 1:13-cv-04740, indicates a 2013 filing in the court’s Newark vicinage.

The litigation followed the standard Hatch-Waxman sequence:

1. Supernus received Actavis’s notice of an ANDA filing and Paragraph IV certification.
2. Supernus filed an infringement complaint within the statutory 45-day period.
3. The filing triggered the statutory 30-month stay of FDA approval, subject to any court decision or other statutory adjustment.
4. The parties litigated claim construction, infringement, validity, and potential launch restrictions.
5. The case ended without a reported trial judgment establishing a final public holding on all asserted claims.

Key procedural timeline

Date or period	Event
2013	Actavis submitted an ANDA with a Paragraph IV certification concerning Trokendi XR patents
2013	Supernus filed Case No. 1:13-cv-04740 in the District of New Jersey
2013-2014	Pleadings, discovery, and Hatch-Waxman motion practice
Before a reported merits decision	Parties resolved the dispute
Post-resolution	No publicly reported Federal Circuit merits opinion appears to have resulted from this docket

What was the outcome of Supernus v. Actavis?

The action was resolved without a publicly reported merits decision determining whether Actavis infringed the asserted Trokendi XR patents or whether those patents were invalid.

The case therefore does not provide the same type of precedential analysis as a final district-court trial judgment or Federal Circuit opinion. Its principal commercial significance arises from the resolution of a Paragraph IV challenge to a branded extended-release product.

Publicly available records do not disclose the complete terms of the parties’ agreement. The resolution should not be interpreted as a judicial confirmation that the asserted patents were valid and infringed. It also should not be treated as a judicial finding that Actavis’s proposed product was noninfringing or that the patents were invalid. Settlement eliminates the litigation risk between the named parties without necessarily resolving the strength of the patent estate against other ANDA applicants.

Did Actavis obtain an authorized generic or an agreed launch date?

The public docket and publicly available company disclosures do not establish a complete set of commercial settlement terms, including whether Actavis received:

• A license to launch before patent expiration.
• A defined launch date.
• An authorized-generic arrangement.
• An option to distribute Supernus’s product.
• A supply agreement.
• A contingent launch right tied to third-party generic entry.

Those terms matter because a Hatch-Waxman settlement can preserve branded exclusivity while permitting a negotiated generic entry date. A settlement can also provide for an earlier launch if another generic manufacturer enters the market, if a patent is invalidated in separate litigation, or if regulatory circumstances change.

No commercial conclusion should be drawn from the dismissal alone. The absence of a public merits opinion means the docket does not establish whether Actavis considered the asserted patents weak, whether Supernus paid or supplied value to Actavis, or whether the parties agreed to an early entry date.

What was the Orange Book status of Trokendi XR?

Trokendi XR’s Orange Book protection depended primarily on patents directed to its extended-release topiramate formulation and related product characteristics. The Orange Book listing provides the statutory foundation for Paragraph IV certifications and the 30-month stay mechanism.

Orange Book and patent-estate considerations

Protection category	Relevance to Trokendi XR
Active ingredient	Limited value because topiramate was already established
Extended-release formulation	Primary technical protection
Drug product claims	Potentially applicable to the capsule and release-control system
Method-of-use claims	Relevant where the generic label includes protected indications
Regulatory exclusivity	Separate from patent protection and dependent on the NDA approval history
Patent-term adjustment or extension	Can affect the effective end date of individual patents
Pediatric exclusivity	Could add six months to eligible patent or exclusivity periods

Patent expiration dates must be calculated from the individual patent records, including patent-term adjustment, terminal disclaimers, and any applicable patent-term extension. The issue date alone is not a reliable expiration-date indicator.

How strong was Supernus’s patent estate?

Supernus’s estate had meaningful commercial value because it protected a differentiated extended-release dosage form rather than merely an active ingredient. The strength of that strategy depended on claim scope and the ability to prove that a competing ANDA product practiced the claimed release technology.

Strengths

The principal strengths were:

• A formulation-based barrier covering a branded extended-release product.
• The ability to assert the patents before generic launch under Section 271(e)(2).
• Potentially narrow but technically specific claims that could read on competing extended-release products.
• The ability to combine formulation claims with later-issued product or method-of-use patents.
• A regulatory framework that delayed approval while the litigation proceeded.

Weaknesses

The estate also carried standard formulation-patent risks:

• Extended-release formulation claims are vulnerable to obviousness challenges based on prior controlled-release technologies.
• Claim construction can determine whether dissolution and release-profile limitations are met.
• Narrow formulation claims may be designed around by an ANDA applicant.
• A patent settlement with one applicant does not bind other generic manufacturers.
• Method-of-use protection may be limited if the generic sponsor uses a permissible skinny label.

The fact that the Actavis dispute ended without a merits opinion leaves the validity and infringement strength of the asserted claims unresolved by precedent.

Were there Paragraph IV challenges to Trokendi XR from other companies?

Trokendi XR faced the broader generic-entry risk associated with ANDA filings and Paragraph IV certifications. Supernus’s public filings identified patent litigation involving additional generic applicants concerning Trokendi XR and other Supernus products.

A settlement with Actavis did not eliminate:

• Challenges by other ANDA sponsors.
• Litigation over later-issued patents.
• Declaratory-judgment actions.
• Regulatory approval after patent expiration.
• Design-around products that avoid the asserted formulation claims.

The competitive assessment therefore requires review of the complete Orange Book listing, later district-court dockets, FDA ANDA approvals, and Supernus’s annual reports for subsequent years.

What litigation risks affected generic launch?

A generic entrant faced several possible launch scenarios.

Scenario 1: Entry after patent expiry

This is the lowest litigation-risk path. The generic may launch after all relevant Orange Book patents and applicable exclusivity periods expire, assuming FDA approval and no separate regulatory barrier.

Scenario 2: Licensed early entry

A settlement may permit launch before the latest listed patent expiration date. The commercial terms may include a fixed date, an earlier-entry trigger, or conditions tied to other litigation.

Scenario 3: At-risk launch

Actavis could have launched before final resolution at the risk of an injunction, damages, or a later finding of infringement. An at-risk launch is less attractive where the formulation patent is central to the product and substitution could materially reduce branded sales.

Scenario 4: Design-around launch

A generic sponsor could modify the release-control system or dissolution profile to avoid the asserted claims. That approach can create new development and bioequivalence risk, particularly for an extended-release product.

What revenue exposure did the case create for Supernus?

Trokendi XR was a strategic product for Supernus. A generic launch could have affected:

• Net product sales.
• Prescriber retention.
• Pharmacy substitution.
• Gross-to-net deductions.
• Managed-care formulary positioning.
• Sales-force economics.
• Valuation of the remaining Supernus patent portfolio.

The revenue impact would depend on the number of approved generics, the timing of entry, the availability of authorized-generic supply, and the extent to which competitors could substitute a different extended-release topiramate product.

A single generic entrant does not always produce immediate full erosion. Extended-release products may face manufacturing constraints, limited initial supply, and slower payer conversion. Once multiple generics enter, price competition generally increases and branded share declines more rapidly.

How does the case compare with conventional small-molecule generic litigation?

Supernus v. Actavis was a conventional small-molecule Hatch-Waxman dispute, not a biologic or biosimilar case.

Issue	Trokendi XR litigation	Biologic biosimilar litigation
Regulatory pathway	ANDA	Biologics license application under the BPCIA
Core product	Small-molecule topiramate	Biologic reference product
Main patent issues	Formulation, release profile, labeling	Composition, manufacturing, formulation, therapeutic use
Launch mechanism	Paragraph IV and 30-month stay	Patent dance and BPCIA notice
Interchangeability	Not generally required for ANDA approval	Separate FDA designation
Manufacturing barriers	Moderate for extended-release capsules	Often substantial for biologics

The technical barrier in this case was pharmaceutical formulation development. It did not involve the complex-cell-line, process-characterization, or biosimilarity issues associated with biologic competition.

What is the litigation status of Case No. 1:13-cv-04740?

The action is closed following resolution between Supernus and Actavis. No reported appellate merits ruling established a binding construction of the asserted patents or a final determination of infringement or invalidity.

For transaction, litigation, or market-entry analysis, the case should be treated as a resolved Hatch-Waxman action with undisclosed commercial terms. It should not be cited as controlling authority on the validity of Supernus’s Trokendi XR patents.

Key Takeaways

• Supernus v. Actavis involved Trokendi XR, an extended-release topiramate product.
• Supernus sued after Actavis filed an ANDA with a Paragraph IV certification.
• The dispute focused on formulation patents, principally the extended-release delivery technology.
• The case ended without a reported merits judgment or Federal Circuit decision.
• Public sources do not disclose the complete settlement terms or a definitive Actavis launch date.
• The settlement removed Actavis as an immediate litigation adversary but did not eliminate generic-entry risk from other ANDA applicants.
• Trokendi XR’s commercial protection depended on the combined effect of Orange Book patents, regulatory exclusivity, formulation complexity, and the timing of competing generic approvals.
• The case provides limited precedent on patent validity because the parties did not litigate the dispute to a reported final merits decision.

FAQs

What was Supernus Pharmaceuticals’ product in the Actavis lawsuit?

The product was Trokendi XR, an extended-release topiramate capsule approved by the FDA in 2013.

Was U.S. Patent No. 8,298,589 invalidated in the case?

No reported decision in Case No. 1:13-cv-04740 invalidated the patent. The case ended without a publicly reported merits determination.

Did the Actavis settlement permit generic Trokendi XR before patent expiration?

The public record does not disclose complete settlement terms sufficient to establish a definitive launch date or license scope.

Was Supernus v. Actavis a biologic patent case?

No. It was a small-molecule Hatch-Waxman case involving an extended-release formulation of topiramate.

Does the settlement prevent other companies from challenging Trokendi XR patents?

No. A settlement binds the parties to that agreement. Other ANDA sponsors may challenge listed patents or pursue a noninfringing design-around, subject to the Orange Book and Hatch-Waxman framework.

References

1. U.S. Food and Drug Administration. (2013). Trokendi XR (topiramate) extended-release capsules: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. District Court for the District of New Jersey. (2013). Supernus Pharmaceuticals, Inc. v. Actavis Inc., No. 1:13-cv-04740.

4. Supernus Pharmaceuticals, Inc. (2013). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. U.S. Patent No. 8,298,589. (2012). Extended release formulations of topiramate. U.S. Patent and Trademark Office.

6. U.S. Patent No. 8,747,897. (2014). Extended release formulations of topiramate. U.S. Patent and Trademark Office.